₹2,000 Monthly SIP in Nippon India Pharma Fund-Growth Plan for 15 Years
If you had started a ₹2,000/month SIP on 28 Sept 2011 and never stopped — through every crash and rally — here is exactly what happened, using Nippon India Pharma Fund-Growth Plan's actual NAV for all 181 installments.
You invested
₹3,62,000
181 installments
Value today
₹14,24,500
28 Sept 2026
Absolute gain
+₹10,62,500
+293.5%
XIRR (annualised)
16.52%
money-weighted
The journey, month by month
Worst fall on the way
-20.7%
Deepest drop from peak. This is what you had to sit through.
Corrections survived
7
Falls of 10%+ during the period. Every one recovered.
Same SIP in a fixed deposit
₹6,73,727
Modelled at historical FD rates. The fund beat FD by ₹7,50,773.
Year-by-year progress
| Year | Invested | Value | Overall gain |
|---|---|---|---|
| Year 1 (28 Sept 2012) | ₹26,000 | ₹30,214 | +16.2% |
| Year 2 (30 Sept 2013) | ₹50,000 | ₹59,497 | +19% |
| Year 3 (29 Sept 2014) | ₹74,000 | ₹1,31,837 | +78.2% |
| Year 4 (28 Sept 2015) | ₹98,000 | ₹1,95,770 | +99.8% |
| Year 5 (28 Sept 2016) | ₹1,22,000 | ₹2,12,707 | +74.3% |
| Year 6 (28 Sept 2017) | ₹1,46,000 | ₹2,07,174 | +41.9% |
| Year 7 (28 Sept 2018) | ₹1,70,000 | ₹2,83,583 | +66.8% |
| Year 8 (30 Sept 2019) | ₹1,94,000 | ₹2,74,041 | +41.3% |
| Year 9 (28 Sept 2020) | ₹2,18,000 | ₹4,73,993 | +117.4% |
| Year 10 (28 Sept 2021) | ₹2,42,000 | ₹6,69,527 | +176.7% |
| Year 11 (28 Sept 2022) | ₹2,66,000 | ₹6,27,162 | +135.8% |
| Year 12 (29 Sept 2023) | ₹2,90,000 | ₹8,30,272 | +186.3% |
| Year 13 (30 Sept 2024) | ₹3,14,000 | ₹12,62,005 | +301.9% |
| Year 14 (29 Sept 2025) | ₹3,38,000 | ₹12,25,104 | +262.5% |
| Year 15 (28 Sept 2026) | ₹3,62,000 | ₹14,24,500 | +293.5% |
Best year of the journey: Year 9 (+59% market move) · Toughest year: Year 6 (-12.5%)
Wealth Time Machine
Watch this exact journey as a 60-second cinematic replay
Every crash headline, every recovery — with your money in it.
Try a different amount
Try a different duration
Past performance does not guarantee future returns. This page shows the historical result of the stated SIP using Nippon India Pharma Fund-Growth Plan's published NAV (source: AMFI) between 28 Sept 2011 and 28 Sept 2026; it is educational research, not investment advice. FD comparison is modelled at historical average FD rates. Mutual fund investments are subject to market risks.